$QNRX News

Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy

Quoin Pharma Announces Publication Of Peer-Reviewed Paper Introducing QRX003 And Its Mechanism Of Action In Netherton Syndrome

Canaccord Genuity Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $18

Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome

Quoin Pharmaceuticals’ Lead Product Candidate QRX003 Granted Orphan Drug Designation By European Medicines Agency For Treatment Of Peeling Skin Syndrome

BTIG Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $14

Quoin Pharmaceuticals Announces Acceptance of QRX003 Paper in Dermatology and Therapy

Quoin Pharmaceuticals Announces Publication Acceptance Of QRX003 Netherton Syndrome Manuscript Featuring Pediatric Compassionate-Use Case Report In Dermatology and Therapy Issue

Lake Street Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $20

Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome

Quoin Pharmaceuticals Releases New NETHERTON NOW Video: Aminah’s Story Featuring Laura Wright-Sexton, MD, the Physician Who First Met Her Daughter in the ICU

CORRECTION -- Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome

Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome

FDA Grants Rare Pediatric Disease Designation For Quoin Pharma’s Lead Asset, QRX003, For Treatment Of Peeling Skin Syndrome

Quoin Pharmaceuticals Announces Private Placement Financing of Up to $50.0 Million

Quoin Pharmaceuticals Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome

Quoin Pharmaceuticals Stock Surges Friday: What's Happening?

QNRX: Believe Conditional FDA Approval of Proposed Brand Name Reflects QRX003 Nearing Potential Commercialization

Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Quoin Pharmaceuticals Q2 EPS $(1.90) Misses $(1.61) Estimate